Nimenrix (MenACWY-TT) / Pfizer  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nimenrix (MenACWY-TT) / Pfizer
2020-004385-19: Long-term safety and tolerability of iptacopan in patients with Paroxysmal Nocturnal Hemoglobinuria

Ongoing
3
165
Europe
iptacopan, LNP023, Capsule, hard, PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml, ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML, MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC, BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO, Nimenrix, HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML
Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Farmacéutica, S.A., Novartis Pharma AG
Paroxysmal Nocturnal Hemoglobinuria (PNH), Blood disorder, Diseases [C] - Immune System Diseases [C20]
 
 
2020-005059-19: A PHASE 3B, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF NIMENRIX® IN HEALTHY INFANTS, GIVEN AT 3 AND 12 MONTHS OF AGE Vaiheen 3b kahdella Nimenrix-annoksella tehty avoin tutkimus vauvoilla

Not yet recruiting
3
150
Europe
Powder and solution for solution for injection, Nimenrix®
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, Pfizer Inc.
Invasive Meningococcal Disease (IMD), Prevention of disease caused by a type of bacteria called NeisseriaI, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT05093829: Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine

Active, not recruiting
3
1325
RoW
NmCV-5, MenACWY-TT, Nimenrix
Emory University, National Institute of Allergy and Infectious Diseases (NIAID)
Meningitis
03/23
07/25
NCT03547271 / 2017-004731-36: Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Hourglass Jan 2023 - Dec 2023 : Data from trial for meningococcal infections
Completed
3
1660
Europe, RoW
MenACYW conjugate vaccine, MenQuadfi®, Meningococcal group A, C, W-135, and Y conjugate vaccine, Nimenrix®, DTaP-IPV-HB-Hib vaccine, Hexyon®/Hexacima®, Pneumococcal vaccine (13-valent), Prevenar 13®, Pneumococcal vaccine (10-valent), Synflorix®, MMR vaccine, M-M-RVAXPRO®
Sanofi Pasteur, a Sanofi Company
Meningococcal Infections
05/23
05/23
NCT06284915: Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers

Recruiting
3
840
Europe, RoW
MenACYW conjugate vaccine, MenQuadfi®, Nimenrix®
Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation, Healthy Volunteers
03/25
03/25
NCT04400838 / 2020-001228-32: Investigating a Vaccine Against COVID-19

Active, not recruiting
2/3
12390
Europe
ChAdOx1 nCoV-19 (Abs 260), MenACWY vaccine, Menveo, Nimenrix, ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost, Two dose MenACWY vaccine, ChAdOx1 nCoV-19 (qPCR), ChAdOx1 nCoV-19 0.5mL prime plus boost, Two dose MenACWY vaccine min. 4 weeks apart, Two dose ChAdOx1 nCoV-19/Covishield 0.5mL, Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL
University of Oxford
Coronavirus
03/24
03/24

Download Options